Key Laboratory for Nano-Bio Interface Research, Division of Nanobiomedicine, Suzhou Institute of NanoTech and NanoBionics, Chinese Academy of Sciences, Suzhou, China.
China-Japan Union Hospital of Jilin University, Changchun, China.
Cell Prolif. 2023 May;56(5):e13451. doi: 10.1111/cpr.13451. Epub 2023 Mar 13.
The strategy of replacing a completely damaged spinal cord with allogenic adult spinal cord tissues (aSCs) can potentially repair complete spinal cord injury (SCI) in combination with immunosuppressive drugs, such as tacrolimus (Tac), which suppress transplant rejection and improve graft survival. However, daily systemic administration of immunosuppressive agents may cause harsh side effects. Herein, a localized, sustained Tac-release collagen hydrogel (Col/Tac) was developed to maximize the immune regulatory efficacy but minimize the side effects of Tac after aSC transplantation in complete SCI recipients. Thoracic aSCs of rat donors were transplanted into the complete thoracic spinal cord transection rat recipients, after which Col/Tac hydrogel was implanted. The Tac-encapsulated collagen hydrogel exhibited suitable mechanical properties and long-term sustained Tac release behaviour. After Col/Tac hydrogel implantation in SCI rats with aSC transplantation, the recipients' survival rate significantly improved and the side effects on tissues were reduced compared with those with conventional Tac medication. Moreover, treatment with the Col/Tac hydrogel exhibited similarly reduced immune rejection levels by regulating immune responses and promoted neurogenesis compared to daily Tac injections, and thus improved functional restoration. Localized delivery of immunosuppressive agents by the Col/Tac hydrogel may be a promising strategy for overcoming immune rejection of transplants, with significant potential for clinical application in the future.
用同种异体成体脊髓组织(aSCs)替代完全损伤的脊髓的策略,结合免疫抑制剂如他克莫司(Tac),可以潜在地修复完全性脊髓损伤(SCI),抑制移植排斥反应并提高移植物存活率。然而,每天进行系统性免疫抑制剂给药可能会导致严重的副作用。在此,我们开发了一种局部、持续释放 Tac 的胶原水凝胶(Col/Tac),以最大限度地发挥 Tac 的免疫调节作用,同时最大限度地减少完全性 SCI 接受者接受 aSC 移植后 Tac 的副作用。用大鼠供体的胸段 aSCs 移植到完全性胸段脊髓横断大鼠受者中,然后植入 Col/Tac 水凝胶。Tac 包封的胶原水凝胶表现出合适的机械性能和长期持续的 Tac 释放行为。与传统 Tac 药物治疗相比,在 SCI 大鼠接受 aSC 移植后植入 Col/Tac 水凝胶后,受者的存活率显著提高,对组织的副作用减少。此外,与每日 Tac 注射相比,Col/Tac 水凝胶治疗通过调节免疫反应同样减少了免疫排斥水平,并促进了神经发生,从而改善了功能恢复。Col/Tac 水凝胶的局部递送免疫抑制剂可能是克服移植免疫排斥的一种很有前途的策略,具有显著的临床应用潜力。